TickerSpark Feed

healthcare

Everything tagged "healthcare" across the TickerSpark archives.

Twist Bioscience Corporation (TWST) rises on earnings misses

Twist Bioscience Corporation (TWST) rises after reporting earnings misses, with shares up 5.5% as investors react to the latest quarterly results.

Aug 3, 2026·2 MIN

Healthcare Medical - Diagnostics & Research

Research ReportAXSM

Axsome Therapeutics (AXSM): Growth Is Strong, Valuation Is Tight

Axsome has evolved into a commercial CNS platform with rapid revenue growth, led by Auvelity and a newly expanded Alzheimer’s agitation opportunity. The stock still earns only a Hold as losses, leverage, and a rich valuation limit upside.

Aug 3, 2026·18 MIN

Healthcare Biotechnology Biotech

Research ReportSNY

Sanofi (SNY): Dupixent Growth Supports a Hold

Sanofi combines strong Dupixent momentum, improving margins, and solid cash generation with a more leveraged balance sheet and a valuation that looks fair rather than cheap. The result is a patient Hold case for medium-term investors.

Aug 3, 2026·21 MIN

Healthcare Drug Manufacturers - General Pharmaceuticals

Research ReportTWST

Twist Bioscience (TWST): Growth Engine, But Valuation Is Rich

Twist Bioscience posted 19.3% revenue growth in fiscal Q2 2026 and raised full-year guidance, but it still faces losses and a demanding valuation. The stock earns a Hold as execution improves while investors wait for profitability.

Aug 3, 2026·22 MIN

Healthcare Diagnostics & Research Biotech

OpinionBTSG

BrightSpring's 18% plunge says guidance is no longer enough

BrightSpring's growth is real, but a 20 million-share secondary offering and a 40.5% latest EPS miss have shifted the trade toward supply and execution risk. Until the stock reclaims key moving averages, the 18.1% plunge looks like a breakdown rather than a buying opportunity.

Aug 1, 2026·3 MIN

Healthcare Valuation Insider Selling

Research ReportAMGN

Amgen (AMGN): Growth Offsets Biosimilar Pressure

Amgen’s portfolio is shifting toward faster-growing products like Repatha, EVENITY, and TEZSPIRE, but leverage and biosimilar erosion keep the stock in Hold territory. MariTide is the key medium-term catalyst, while Prolia and XGEVA remain the biggest drag.

Aug 1, 2026·19 MIN

Healthcare Drug Manufacturers - General Biotech

Research ReportLIN

Linde plc (LIN): Pricing Power Supports a Hold

Linde is delivering steady growth, margin expansion, and raised EPS guidance, but the stock trades at a premium valuation that keeps the call at Hold.

Jul 31, 2026·21 MIN

Basic Materials Specialty Chemicals Industrial Gases

Research ReportSYK

Stryker (SYK): Mako Growth Supports a Buy

Stryker’s Q2 execution, Mako robotics momentum, and raised full-year outlook support a Buy, though valuation leaves limited room for error. Cybersecurity, supply disruption, and tariff pressure keep the risk profile disciplined.

Jul 31, 2026·23 MIN

Healthcare Medical Devices Healthcare

Research ReportGSK

GlaxoSmithKline PLC ADR (GSK): Specialty Medicines Drive Growth

GSK is leaning on specialty medicines, Shingrix, and a strong HIV franchise to offset declines in legacy categories. The stock looks fairly valued with modest upside, making it more of a steady Hold than a high-conviction buy.

Jul 31, 2026·18 MIN

Healthcare Drug Manufacturers - General Healthcare

Research ReportCORT

Corcept Therapeutics (CORT): Growth Upside vs. Rich Valuation

Corcept has a strong commercial base, a newly approved oncology product, and raised 2026 guidance, but the stock still screens as expensive. The report lands on a Hold as earnings pressure and execution risk offset the long-term growth story.

Jul 29, 2026·21 MIN

Healthcare Biotechnology Biotech

Earnings AnalysisHUM

Humana Inc. (HUM) drops on earnings beat, margin deep dive

Humana Inc. (HUM) beat second-quarter EPS and revenue estimates, yet the stock dropped as investors focused on Medicare Advantage margin repair, cost-ratio improvement, and 2027 bid strategy. This deep-dive examines why the earnings beat wasn’t enough to offset longer-term execution risks.

Jul 29, 2026·7 MIN

Healthcare Medical - Healthcare Plans

Earnings AnalysisGEHC

GE HealthCare Technologies Inc. (GEHC) climbs on deep earnings

GE HealthCare Technologies Inc. (GEHC) climbs after a detailed earnings beat, with EPS and revenue topping estimates, orders and backlog hitting records, and imaging and pharmaceutical diagnostics offsetting weakness in Patient Care Solutions. The full analysis looks beyond the headline move to segment trends, margins, and the turnaround path ahead.